44 2033180199

A case series for the evaluation of dalbavancin in vancomycin allergic patients

Sara Diaz

AIM: Considering the possibility of cross-reactivity between the two glycol-peptide antibiotics, there is a dearth of information about the usage of Dalbavancin in individuals with a Vancomycin allergy.

METHODS: Patients who received Dalbavancin as an outpatient infusion and had a reported Vancomycin allergy in the electronic health record were subjected to a retrospective medical record analysis between February 2016 and February 2021.

FINDINGS: During the trial period, Dalbavancin was infused as an outpatient in 559 distinct patients, 10 of whom had a Vancomycin allergy that was noted in the electronic health record. One patient experienced delayed rash, two patients reported a reaction to Vancomycin infusion, two patients reported acute kidney damage, and one patient reported intolerance with general malaise. Four of the ten patients had a history of a type I IgGmediated reaction to Vancomycin. Dalbavancin was administered to all 10 patients at least once, with no side effects being reported.

Publication d'évaluation par les pairs pour les associations, les sociétés et les universités pulsus-health-tech